Skip to main content

Table 3 Annual direct medical costs for patients with ischaemic heart disease, ischaemic stroke, haemorrhagic stroke and hypertensive heart disease by disease stage attending two hospitals in Cameroon, 2013–2017

From: Estimation and determinants of direct medical costs of ischaemic heart disease, stroke and hypertensive heart disease: evidence from two major hospitals in Cameroon

 

IHD

I-stroke

H-stroke

HHD

Acute

(n = 60, 65.2%)

Prevalent

(n = 32, 34.8%)

Acute

(n = 224, 70.6%)

Prevalent

(n = 93, 29.4%)

Acute

(n = 147, 76.2%)

Prevalent

(n = 46, 23.8%)

Acute

(n = 115, 46.4%)

Prevalent

(n = 133, 53.6%)

Consultation

5700 (4200)

6400 (5700)

13,900 (10,100)

13,100 (9100)

10,700 (7500)

9400 (6700)

7300 (7900)

7200 (7000)

[10.3 (7.6)]

11.6 (10.3)]

[25.2 (18.3)]

[23.7 (16.5)]

[19.4 (13.6)]

[17.0 (12.1)]

[13.2 (14.3)]

[13.0 (12.6)]

Laboratory tests

84,600 (55,000)

104,800 (59,100)

110,800 (76,700)

111,700 (68,700)

99,900 (77,200)

101,500 (93,000)

99,300 (114,900)

93,600 (102,800)

[153.1 (99.6)]

[189.7 (106.9)]

[200.6 (138.8)]

[211.8 (124.3)]

[180.8 (139.7)]

[183.7 (168.3)]

[179.7 (208.0)]

[169.4 (186.1)]

Imaging and procedures

1,526,100 (1,569,600)*

581,100 (766,100)

196,100 (119,200)

186,500 (106,700)

206,100 (355,300)

144,900 (121,400)

86,400 (172,300)

60,200 (39,400)

[2762.5 (2841.2)]

[1051.8 (1386.7)]

[354.9 (215.8)]

[337.6 (193.1)]

[373.1 (643.1)]

[262.3 (219.7)]

[156.4 (311.9)]

[109.0 (71.3)]

Medication

206,700 (197,800)

181,800 (197,200)

330,700 (224,500)

338,000 (272,000)

298,000 (233,700)

270,500 (181,400)

176,000 (132,700)

158,400 (103,300)

[374.1 (258.0)]

[329.1 (356.9)]

[598.6 (406.4)]

[611.8 (492.3)]

[539.4 (423.0)]

[489.6 (328.3)]

[318.6 (240.2)]

[286.7 (187.0)]

Hospitalization

26,000 (40,700)

37,500 (61,700)

164,800 (171,100)

193,100 (289,400)

259,700 (297,100)

186,700 (207,000)

46,600 (75,500)

36,200 (40,400)

[47.0 (73.7)]

[67.9 (111.7)]

[298.3 (309.7)]

[349.5 (523.8)]

[470.1 (537.8)]

[337.9 (374.7)]

[84.3 (136.7)]

[65.5 (73.1)]

Physiotherapy

–

–

564,900 (519,100)

607,200 (477,000)

380,900 (348,000)

429,500 (411,400)

–

–

   

[1022.5 (939.6)]

[1099.1 (863.4)]

[689.5 (629.9)]

[777.4 (744.7)]

  

Total

1,849,100 (1,602,700)*

911,500 (708,700)

920,000 (621,500)

960,600 (794,600)

827,400 (735,900)

776,900 (604,200)

400,500 (351,500)

346,600 (241,300)

[3347.1 (2901.1)]

[1650.0 (1282.8)]

[1665.3 (1125.0)]

[1738.8 (1438.3)]

[1497.7 (1332.0)]

[1406.3 (1093.7)]

[725.0 (636.2)]

[627.4 (436.8)]

  1. Costs are means (standard deviations). Patients were categorized as ‘acute’ as those who presented as a first ever CVD event, while a patient was categorized as ‘prevalent’ if they had a documented history of prior CVD event. Costs are in Central African francs (XAF). For ease with comparisons, equivalent costs expressed in United States dollars (USD) are presented in square brackets. CVD Cardiovascular disease, IHD Ischaemic heart disease, I-stroke Ischaemic stroke, H-stroke Haemorrhagic stroke, HHD Hypertensive heart disease. *significant difference between acute and prevalent IHD for imaging & procedure cost category and for total costs (p < 0.01)
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us